Table 3
Per protocol analysis of change in primary and secondary outcome measures over 6 weeks in the vitamin E and placebo groups
| Outcome | Vitamin E (n = 30) | Placebo (n = 34) | Difference* (95% CI) | p value |
|---|---|---|---|---|
| FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity. | ||||
| *Differences in log terms for IgE were anti-logged to give ratio of IgE values, final/baseline and vitamin E/placebo. | ||||
| †Analysis by the Mann-Whitney U test with median change. | ||||
| ‡Analysis by χ2 test. | ||||
| ¶Confidence intervals not calculated for difference in medians. | ||||
| Mean (SD) change in bronchial reactivity (DD) | +0.38 (2.38) | 0.00 (1.45) | +0.38 (−0.59 to +1.35) | 0.44 |
| Mean (SD) change in FEV1 (ml) | +26 (138) | −27 (212) | +53 (−38 to +143) | 0.25 |
| Mean (SD) change in FVC (ml) | +25 (177) | −16 (313) | +41 (−88 to +170) | 0.53 |
| Mean (SD) change in AM peak flow (l/min) | +1 (25) | −3 (21) | +4 (−7 to +16) | 0.48 |
| Median (range) change in bronchodilator use (puffs/day)† | 0 (−3 to +2) | 0 (−8 to +5) | 0¶ | 0.65 |
| Median (range) change in daytime symptom score | 0 (−1 to +1) | 0 (−1 to +2) | 0¶ | 0.68 |
| Median (range) change in night time symptom score | 0 (−2 to +1) | 0 (−1 to +2.5) | 0¶ | 0.92 |
| Mean (SD) change in IgE* ratio | 0.98 (1.24) | 0.95 (1.54) | 1.03 (0.87 to 1.23) | 0.73 |
| Loss of atopic response‡ | 7/30 (23%) | 5/34 (15%) | 9% (−10 to 28) | 0.57 |
